RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 287 shares, a decrease of 80.1% from the July 30th total of 1,444 shares. Based on an average daily trading volume, of 113 shares, the days-to-cover ratio is presently 2.5 days. Approximately 0.0% of the shares of the company are short sold.

RCN Pareto Strategic Allocation ETF Trading Up 0.5%

Shares of NYSEARCA PRTO traded up $0.15 during midday trading on Thursday, reaching $28.53. 309 shares of the stock were exchanged. The company has a market capitalization of $17.97 million, a price-to-earnings ratio of -29.72 and a beta of 1.07. The firm has a 50-day moving average price of $27.72. RCN Pareto Strategic Allocation ETF has a twelve month low of $24.68 and a twelve month high of $28.58.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.